Recommendations for Intraoperative Adverse Events Data Collection in Clinical Studies and Study Protocols. An ICARUS Global Surgical Collaboration Study. - Abstract - Europe PMC

Europe PMC is an archive of life sciences journal literature.

Recommendations for Intraoperative Adverse Events Data Collection in Clinical Studies and Study Protocols. An ICARUS Global Surgical Collaboration Study. - Abstract - Europe PMC

Inderbir Gill

Women are predisposed to early dose‐limiting toxicities during adjuvant CAPOX for colorectal cancer - Nozawa - 2021 - International Journal of Clinical Practice - Wiley Online Library

Visual Abstracts: Innovations: Sage Journals

ICARUS Global Surgical Collaboration Project (@ICARUS_collab) / X

European Urology Today Vol. 33 No.5 – October 2021/ January 2022 by European Association of Urology (EAU) - Issuu

The effect of intraoperative wound protector use on the risk of surgical site infections in patients undergoing pancreatoduodenectomy: a systematic review and meta-analysis

PDF) The Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) Global Surgical Collaboration Project: Development of Criteria for Reporting Adverse Events During Surgical Procedures and Evaluating Their Impact on the

Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular

European Urology Today Vol. 33 No.5 – October 2021/ January 2022 by European Association of Urology (EAU) - Issuu

PDF) Recommendations for Intraoperative Adverse Events Data Collection in Clinical Studies and Study Protocols. An ICARUS Global Surgical Collaboration Study

Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular

Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study)